San Francisco - Five Prime
Therapeutics, Inc. announced today to have entered into a two year
collaborative research and license agreement with Boehringer Ingelheim to
discover novel therapeutic products to treat rheumatoid arthritis and other
diseases. In a multi product deal potentially worth over $75 million, FivePrime
will receive an upfront fee and research support, and Boehringer Ingelheim has
exclusive worldwide rights to develop and commercialize products and targets
discovered in exchange for future milestones and royalties. Further details of the agreement have not
“FivePrime’s comprehensive protein discovery program is providing a wealth of valuable therapeutic candidates in multiple disease areas. We are very excited to partner with Boehringer Ingelheim, given their leadership in protein manufacturing, their commitment to biotherapeutics and their excellent partnering track record”, commented Gail Maderis, FivePrime’s President and Chief Executive Officer. “We believe that combining Boehringer Ingelheim’s excellence in product research and development with FivePrime’s powerful protein discovery engine will increase the likelihood and speed of discovering and developing new therapeutics for patients in need”, added Lewis T. “Rusty” Williams, FivePrime’s founder and Executive Chairman.
The basis for the collaboration is FivePrime’s comprehensive, rapid protein discovery system. FivePrime’s protein screening library contains essentially all human secreted proteins and their receptors, including many that are unavailable in public collections. FivePrime screens its protein library in complex, primary cell assays with a level of precision, speed and thoroughness previously achievable only in small molecule screening. Using technologies for rapid in vivo validation of hits from its screens, FivePrime aims to reduce time from idea to an Investigational New Drug.
Boehringer Ingelheim is addressing the unmet medical need of major human diseases with the discovery of novel active principles. “We believe that the combined capabilities of FivePrime and Boehringer Ingelheim will offer new opportunities to discover important disease targets and develop novel drug candidates”, said Mikael Dolsten, Executive Vice President of Pharma Research at Boehringer Ingelheim. “We look forward to the opportunity to collaborate with FivePrime and explore their innovative protein based approaches.”
FivePrime is a privately held protein therapeutics discovery and development company located in San Francisco’s Mission Bay. Its proprietary discovery platform allows the rapid screening of the complete set of secreted proteins and their receptors in medically relevant, cell-based assays to identify new biotherapeutics. FivePrime is applying its high throughput biologics discovery system first in the areas of oncology, metabolic disease, immunology and regenerative medicine with lead proteins in pre-clinical development to treat cancer and type II diabetes. Additional information about FivePrime can be found at www.fiveprime.com .
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development.
For more information please visit www.boehringer-ingelheim.com.